|Clinical and Regulatory|
|Event Type:||Phase 2 Results|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|Disease and Treatment|
|Treatment Name:||Iclusig (ponatinib)|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 10, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the first patient has been treated in its OPTIC (Optimizing PonatinibTreatment In CML) trial of Iclusig® (ponatinib). This randomized, dose-ranging trial is designed to evaluate three starting doses of ponatinib in patients with refractory, chronic-phase chronic myeloid leukemia (CP-CML) and is expected to inform the optimal use of Iclusig in these patients. Approximately 450 patients will be enrolled at clinical sites around the world.
Preliminary data from the OPTIC trial is expected at the end of 2016.